Timothy Robert Malinowski Jr., AGACNP-BC

Timothy Malinowski practices at Prisma Health Hillcrest Hospital in Simpsonville, South Carolina, part of Prisma Health.

Timothy Malinowski's NPI, 1740893593, was assigned on August 30, 2020. Timothy Malinowski holds South Carolina license 24219.

Timothy Malinowski's primary practice is Prisma Health Hillcrest Hospital, at 741 South East Main Street, Simpsonville, SC 29681 in Greenville County. The practice phone is (864) 454-6100. Timothy Malinowski also practices at Hillcrest Hospital, 729 SE Main St, Simpsonville, SC 29681.

Timothy Malinowski's primary practice is Prisma Health Hillcrest Hospital in Simpsonville, South Carolina, part of Prisma Health. Timothy Malinowski is also affiliated with Prisma Health Greenville Memorial Hospital. The medical group on file is Prisma Health Medical Group. Dmand AI also links Timothy Malinowski to 2 more hospitals, 1 group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Timothy Malinowski practices, 5 sites in all. Vendor and product names are available with a free account.

Gerontology is Timothy Malinowski's primary specialty in the NPI Registry, under taxonomy code 363LG0600X. Timothy Malinowski is licensed in South Carolina.

CMS counts 69 Medicare patients who saw Timothy Malinowski in 2024. The largest group is 75 to 84, with 28 patients. 75% of them have heart failure, and 75% have high blood pressure. Their average risk score is 3.02, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Timothy Malinowski's median patient age at 72, with 49% women.

In 2024, Timothy Malinowski wrote 2,518 Medicare Part D claims for 504 patients. 73% of them were for generic drugs.

Timothy Malinowski accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 45 general payments to Timothy Malinowski from 18 drug and device companies in 2025. Consulting fees make up the largest share, 75% of the total. Endotronix, Inc. paid the most, $19,529.